We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Gilead Sciences recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead Sciences has declared a quarterly dividend to stockholders on record at the close of business on March 14, 2025. (Reuters) Gilead Sciences, with a market capitalization of $143.8 billion ...

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market ...

Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $119.96. The business has a fifty day simple moving average of $100.99 and a 200 day simple moving average of $92.33.

Gilead Sciences, Inc. (NASDAQ:GILD), a prominent player in the biotechnology industry with a market capitalization of $142 billion, disclosed on Monday the departure of its Senior Vice President ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $120.00. The company’s shares closed yesterday at $114.43.

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...